otomaqaqaba.blogspot.com
Hematide is in a Phases III trial. Renton led Onyx for nearly 15 years, steppinfg down in February 2008as president, CEO, chairman and a membet of Onyx’s board. At the company, he helped negotiatd a research, development and commercialization partnership with that resulteds inthe anti-cancer drug Nexavar. Nexavare tablets, which cost about $5,0000 a month in the United Stateas and areapproaching $1 billion in annuao sales, are approved in more than 80 countries to treatr kidney cancer and 70-plud countries for liver cancer. Prior to joininy Onyx, Renton was president and COO of Chiron, whic acquired Cetus in 1991.
Renton had been presidenf of Cetussince 1990, COO since 1987 and CFO from 1983 to 1987. Rentob also serves on the boardsof , Cephei and the Special Olympics of Northern California.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment